Europeiska unionen - svenska - EMA (European Medicines Agency)

swedish orphan biovitrum ab (publ) - palifermin - mukosit - alla andra terapeutiska produkter - kepivance är indicerat för att minska incidensen, varaktighet och svårighetsgrad av oral mukosit hos vuxna patienter med hematologiska maligniteter som fått myeloablativ radiokemoterapi associerad med hög förekomst av svår mukosit och som kräver support för autolog---hematopoetisk.

Europeiska unionen - svenska - EMA (European Medicines Agency)

lupin europe gmbh - mexiletine hydrochloride - myotonic störningar - hjärtbehandling - namuscla är indicerat för symtomatisk behandling av myotonia hos vuxna patienter med icke-dystrofa myotonic störningar.

Europeiska unionen - svenska - EMA (European Medicines Agency)

aop orphan pharmaceuticals gmbh - ropeginterferon alfa-2b - polycytemia vera - immunstimulatorer, - besremi är indicerat som monoterapi hos vuxna för behandling av polycytemi vera utan symtomatisk splenomegali.

Europeiska unionen - svenska - EMA (European Medicines Agency)

sfl pharmaceuticals deutschland gmbh - nyxthracis - anthrax - immunförsvaret sera och immunglobuliner, - obiltoxaximab sfl is indicated in combination with appropriate antibacterial drugs in all age groups for treatment of inhalational anthrax due to bacillus anthracis (see section 5. obiltoxaximab sfl is indicated in all age groups for post-exposure prophylaxis of inhalational anthrax when alternative therapies are not appropriate or are not available (see section 5.

Europeiska unionen - svenska - EMA (European Medicines Agency)

roche registration gmbh  - risdiplam - muskelatrofi, ryggrad - andra droger för sjukdomar i muskel-skelettsystemet - evrysdi is indicated for the treatment of 5q spinal muscular atrophy (sma) in patients with a clinical diagnosis of sma type 1, type 2 or type 3 or with one to four smn2 copies.

Europeiska unionen - svenska - EMA (European Medicines Agency)

roche registration gmbh - satralizumab - neuromyelitis optica - immunsuppressiva - satralizumab (enspryng) is indicated as a monotherapy or in combination with immunosuppressive therapy (ist) for the treatment of neuromyelitis optica spectrum disorders (nmosd) in adult and adolescent patients from 12 years of age who are anti-aquaporin-4 igg (aqp4-igg) seropositive.

Europeiska unionen - svenska - EMA (European Medicines Agency)

roche registration gmbh - mosunetuzumab - lymfom, follikel - antineoplastic agents, monoclonal antibodies - lunsumio as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (fl) who have received at least two prior systemic therapies.

Europeiska unionen - svenska - EMA (European Medicines Agency)

aop orphan pharmaceuticals gmbh - sugammadex sodium - neuromuskulär blockade - alla andra terapeutiska produkter - reversering av neuromuskulär blockad som induceras av rocuronium eller vekuronium. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

Europeiska unionen - svenska - EMA (European Medicines Agency)

csl behring gmbh - etranacogene dezaparvovec - hemofili b - other hematological agents - treatment of severe and moderately severe haemophilia b (congenital factor ix deficiency) in adult patients without a history of factor ix inhibitors.

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

animedica gmbh - butorfanoltartrat - injektionsvätska, lösning - 4 mg/ml - butorfanoltartrat 5,83 mg aktiv substans - butorfanol - hund, katt